Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Filings indexed 310 across all filing types
Latest filing 2022-07-27 Director's Dealing
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-07-27 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-27 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-27 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-27 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-07 English
FORM 3 SUBMISSION
Director's Dealing
2022-07-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.